Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
CAMBRIDGE, Mass., March 16, 2016 -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment strategies, today announced that advances within the company’s immuno-oncology pipeline will be presented during two poster presentations on Sunday, April 17, 2016 at the American Association of Cancer Research (AACR) Annual Meeting 2016. The meeting is being held April 16-20, 2016 at the Ernest N. Morial Convention Center in New Orleans.
The abstracts are now available on the AACR website. Jounce’s presentation details are as follows:
Title: Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody
Abstract Code: 573
Poster Number: 4
Poster Session: PO.IM02.09 Therapeutic Antibodies
Date: Sunday, April 17, 2016
Session Time: 1:00-5:00p.m. ET
Location: Section 27
Title: Discovery of a novel TIM3 binding partner and a key role for TIM3 on macrophages: identification of specific antibodies capable of converting immune-suppressive macrophages to immune-enhancing
Abstract Number: 586
Poster Number: 17
Poster Session: PO.IM02.09 Therapeutic Antibodies
Date: Sunday, April 17, 2016
Session Time: 1:00-5:00p.m. ET
Location: Section 27
About Jounce Therapeutics
Jounce Therapeutics is an immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers, designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s translational science platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected]
